This study focuses on people with Acromegaly, a condition caused by a tumor in the pituitary gland that produces excess growth hormone. The research evaluates a new medication called ALXN2420 used together with existing treatments called somatostatin analogs (octreotide acetate or lanreotide acetate). These medications help control the excessive hormone production that causes the symptoms of acromegaly.
The purpose of this study is to determine if ALXN2420 can help lower levels of a hormone called IGF-1 in people with acromegaly when combined with standard treatments. The study compares ALXN2420 to placebo, with both being given alongside regular acromegaly medications. The treatment period lasts for 15 weeks, during which participants receive either ALXN2420 or placebo through injections under the skin.
Throughout the study, participants continue their regular acromegaly medications, which are given as injections either into the muscle or under the skin once every four weeks. The study monitors how well the combination of treatments works by measuring hormone levels and tracking any changes in symptoms. Participants also complete questionnaires about their quality of life and overall health during the study period.
Denmark 
Hungary 
Italy 
Lithuania 
Poland 
Romania 
The Netherlands 
